Intrinsic value of Blueprint Medicines - BPMC

Previous Close

$52.26

  Intrinsic Value

$6.13

stock screener

  Rating & Target

str. sell

-88%

Previous close

$52.26

 
Intrinsic value

$6.13

 
Up/down potential

-88%

 
Rating

str. sell

We calculate the intrinsic value of BPMC stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 2.3

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  34
  53
  79
  115
  162
  223
  299
  393
  506
  639
  793
  969
  1,169
  1,390
  1,635
  1,902
  2,190
  2,501
  2,832
  3,185
  3,557
  3,949
  4,360
  4,790
  5,240
  5,709
  6,197
  6,705
  7,234
  7,783
Variable operating expenses, $m
  124
  192
  287
  416
  587
  807
  1,083
  1,422
  1,830
  2,311
  2,870
  3,508
  4,229
  5,032
  5,916
  6,882
  7,927
  9,051
  10,251
  11,525
  12,872
  14,290
  15,778
  17,336
  18,964
  20,661
  22,428
  24,267
  26,178
  28,165
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  124
  192
  287
  416
  587
  807
  1,083
  1,422
  1,830
  2,311
  2,870
  3,508
  4,229
  5,032
  5,916
  6,882
  7,927
  9,051
  10,251
  11,525
  12,872
  14,290
  15,778
  17,336
  18,964
  20,661
  22,428
  24,267
  26,178
  28,165
Operating income, $m
  -90
  -139
  -207
  -301
  -425
  -584
  -784
  -1,029
  -1,324
  -1,672
  -2,077
  -2,539
  -3,060
  -3,641
  -4,281
  -4,980
  -5,737
  -6,550
  -7,418
  -8,340
  -9,315
  -10,341
  -11,418
  -12,546
  -13,724
  -14,952
  -16,231
  -17,561
  -18,945
  -20,383
EBITDA, $m
  -87
  -135
  -202
  -292
  -413
  -567
  -761
  -1,000
  -1,286
  -1,625
  -2,017
  -2,466
  -2,973
  -3,537
  -4,159
  -4,838
  -5,573
  -6,363
  -7,206
  -8,102
  -9,048
  -10,045
  -11,092
  -12,187
  -13,331
  -14,524
  -15,766
  -17,059
  -18,403
  -19,799
Interest expense (income), $m
  0
  0
  2
  7
  14
  24
  36
  53
  73
  98
  129
  164
  206
  253
  307
  366
  432
  503
  581
  664
  753
  847
  947
  1,052
  1,163
  1,278
  1,399
  1,525
  1,656
  1,792
  1,934
Earnings before tax, $m
  -90
  -141
  -215
  -315
  -448
  -620
  -836
  -1,102
  -1,422
  -1,801
  -2,241
  -2,745
  -3,313
  -3,948
  -4,647
  -5,412
  -6,240
  -7,131
  -8,082
  -9,093
  -10,162
  -11,288
  -12,471
  -13,709
  -15,002
  -16,351
  -17,755
  -19,217
  -20,737
  -22,317
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -90
  -141
  -215
  -315
  -448
  -620
  -836
  -1,102
  -1,422
  -1,801
  -2,241
  -2,745
  -3,313
  -3,948
  -4,647
  -5,412
  -6,240
  -7,131
  -8,082
  -9,093
  -10,162
  -11,288
  -12,471
  -13,709
  -15,002
  -16,351
  -17,755
  -19,217
  -20,737
  -22,317

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  129
  200
  299
  434
  612
  841
  1,129
  1,483
  1,908
  2,410
  2,992
  3,658
  4,409
  5,246
  6,169
  7,176
  8,266
  9,438
  10,688
  12,017
  13,421
  14,900
  16,452
  18,077
  19,774
  21,543
  23,386
  25,303
  27,297
  29,369
Adjusted assets (=assets-cash), $m
  129
  200
  299
  434
  612
  841
  1,129
  1,483
  1,908
  2,410
  2,992
  3,658
  4,409
  5,246
  6,169
  7,176
  8,266
  9,438
  10,688
  12,017
  13,421
  14,900
  16,452
  18,077
  19,774
  21,543
  23,386
  25,303
  27,297
  29,369
Revenue / Adjusted assets
  0.264
  0.265
  0.264
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
Average production assets, $m
  25
  39
  58
  84
  118
  162
  218
  286
  368
  464
  576
  705
  850
  1,011
  1,188
  1,382
  1,592
  1,818
  2,059
  2,315
  2,586
  2,871
  3,170
  3,483
  3,810
  4,150
  4,505
  4,875
  5,259
  5,658
Working capital, $m
  -55
  -85
  -127
  -185
  -261
  -358
  -481
  -632
  -813
  -1,027
  -1,275
  -1,559
  -1,879
  -2,236
  -2,629
  -3,058
  -3,522
  -4,022
  -4,555
  -5,121
  -5,719
  -6,349
  -7,011
  -7,703
  -8,426
  -9,180
  -9,965
  -10,782
  -11,632
  -12,515
Total debt, $m
  28
  91
  180
  302
  462
  668
  927
  1,246
  1,628
  2,080
  2,604
  3,204
  3,880
  4,633
  5,463
  6,370
  7,351
  8,405
  9,531
  10,727
  11,991
  13,321
  14,718
  16,180
  17,708
  19,300
  20,959
  22,684
  24,478
  26,343
Total liabilities, $m
  116
  180
  269
  390
  551
  757
  1,016
  1,334
  1,717
  2,169
  2,693
  3,292
  3,969
  4,722
  5,552
  6,458
  7,439
  8,494
  9,620
  10,815
  12,079
  13,410
  14,807
  16,269
  17,796
  19,389
  21,047
  22,773
  24,567
  26,432
Total equity, $m
  13
  20
  30
  43
  61
  84
  113
  148
  191
  241
  299
  366
  441
  525
  617
  718
  827
  944
  1,069
  1,202
  1,342
  1,490
  1,645
  1,808
  1,977
  2,154
  2,339
  2,530
  2,730
  2,937
Total liabilities and equity, $m
  129
  200
  299
  433
  612
  841
  1,129
  1,482
  1,908
  2,410
  2,992
  3,658
  4,410
  5,247
  6,169
  7,176
  8,266
  9,438
  10,689
  12,017
  13,421
  14,900
  16,452
  18,077
  19,773
  21,543
  23,386
  25,303
  27,297
  29,369
Debt-to-equity ratio
  2.140
  4.560
  6.030
  6.950
  7.550
  7.950
  8.210
  8.400
  8.530
  8.630
  8.700
  8.760
  8.800
  8.830
  8.860
  8.880
  8.890
  8.910
  8.920
  8.930
  8.930
  8.940
  8.950
  8.950
  8.960
  8.960
  8.960
  8.960
  8.970
  8.970
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -90
  -141
  -215
  -315
  -448
  -620
  -836
  -1,102
  -1,422
  -1,801
  -2,241
  -2,745
  -3,313
  -3,948
  -4,647
  -5,412
  -6,240
  -7,131
  -8,082
  -9,093
  -10,162
  -11,288
  -12,471
  -13,709
  -15,002
  -16,351
  -17,755
  -19,217
  -20,737
  -22,317
Depreciation, amort., depletion, $m
  3
  4
  6
  9
  12
  17
  22
  29
  38
  48
  59
  73
  88
  104
  123
  143
  164
  187
  212
  239
  267
  296
  327
  359
  393
  428
  464
  503
  542
  583
Funds from operations, $m
  -87
  -137
  -209
  -307
  -436
  -604
  -814
  -1,073
  -1,385
  -1,753
  -2,182
  -2,672
  -3,226
  -3,844
  -4,525
  -5,269
  -6,076
  -6,943
  -7,870
  -8,854
  -9,896
  -10,993
  -12,144
  -13,350
  -14,609
  -15,923
  -17,291
  -18,714
  -20,195
  -21,733
Change in working capital, $m
  -21
  -30
  -42
  -57
  -76
  -98
  -123
  -151
  -181
  -214
  -248
  -284
  -320
  -357
  -393
  -429
  -465
  -499
  -533
  -566
  -598
  -630
  -661
  -692
  -723
  -754
  -785
  -817
  -849
  -883
Cash from operations, $m
  -67
  -107
  -167
  -249
  -360
  -506
  -691
  -922
  -1,203
  -1,539
  -1,933
  -2,388
  -2,906
  -3,487
  -4,132
  -4,840
  -5,611
  -6,444
  -7,337
  -8,288
  -9,297
  -10,362
  -11,483
  -12,657
  -13,886
  -15,169
  -16,506
  -17,897
  -19,345
  -20,850
Maintenance CAPEX, $m
  -2
  -3
  -4
  -6
  -9
  -12
  -17
  -22
  -29
  -38
  -48
  -59
  -73
  -88
  -104
  -123
  -143
  -164
  -187
  -212
  -239
  -267
  -296
  -327
  -359
  -393
  -428
  -464
  -503
  -542
New CAPEX, $m
  -10
  -14
  -19
  -26
  -34
  -44
  -55
  -68
  -82
  -97
  -112
  -128
  -145
  -161
  -178
  -194
  -210
  -226
  -241
  -256
  -271
  -285
  -299
  -313
  -327
  -341
  -355
  -369
  -384
  -399
Cash from investing activities, $m
  -12
  -17
  -23
  -32
  -43
  -56
  -72
  -90
  -111
  -135
  -160
  -187
  -218
  -249
  -282
  -317
  -353
  -390
  -428
  -468
  -510
  -552
  -595
  -640
  -686
  -734
  -783
  -833
  -887
  -941
Free cash flow, $m
  -78
  -123
  -190
  -281
  -403
  -562
  -764
  -1,013
  -1,315
  -1,674
  -2,093
  -2,576
  -3,123
  -3,736
  -4,414
  -5,157
  -5,964
  -6,834
  -7,765
  -8,757
  -9,807
  -10,914
  -12,078
  -13,297
  -14,572
  -15,902
  -17,288
  -18,731
  -20,232
  -21,792
Issuance/(repayment) of debt, $m
  26
  63
  89
  121
  160
  206
  259
  318
  383
  452
  524
  599
  676
  753
  830
  906
  981
  1,054
  1,126
  1,196
  1,264
  1,331
  1,397
  1,462
  1,527
  1,592
  1,658
  1,726
  1,794
  1,865
Issuance/(repurchase) of shares, $m
  114
  148
  225
  329
  466
  643
  865
  1,138
  1,465
  1,851
  2,299
  2,811
  3,389
  4,031
  4,740
  5,513
  6,349
  7,248
  8,207
  9,226
  10,303
  11,436
  12,626
  13,871
  15,172
  16,528
  17,940
  19,409
  20,936
  22,524
Cash from financing (excl. dividends), $m  
  140
  211
  314
  450
  626
  849
  1,124
  1,456
  1,848
  2,303
  2,823
  3,410
  4,065
  4,784
  5,570
  6,419
  7,330
  8,302
  9,333
  10,422
  11,567
  12,767
  14,023
  15,333
  16,699
  18,120
  19,598
  21,135
  22,730
  24,389
Total cash flow (excl. dividends), $m
  62
  88
  124
  169
  223
  287
  361
  443
  533
  629
  730
  835
  941
  1,049
  1,156
  1,262
  1,366
  1,468
  1,568
  1,665
  1,760
  1,853
  1,945
  2,036
  2,127
  2,218
  2,310
  2,403
  2,498
  2,597
Retained Cash Flow (-), $m
  -114
  -148
  -225
  -329
  -466
  -643
  -865
  -1,138
  -1,465
  -1,851
  -2,299
  -2,811
  -3,389
  -4,031
  -4,740
  -5,513
  -6,349
  -7,248
  -8,207
  -9,226
  -10,303
  -11,436
  -12,626
  -13,871
  -15,172
  -16,528
  -17,940
  -19,409
  -20,936
  -22,524
Prev. year cash balance distribution, $m
  635
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  583
  -60
  -100
  -160
  -243
  -356
  -504
  -695
  -932
  -1,222
  -1,569
  -1,977
  -2,447
  -2,982
  -3,584
  -4,250
  -4,983
  -5,780
  -6,639
  -7,561
  -8,543
  -9,583
  -10,681
  -11,835
  -13,045
  -14,310
  -15,630
  -17,006
  -18,438
  -19,927
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  559
  -55
  -87
  -132
  -188
  -258
  -341
  -434
  -535
  -641
  -745
  -843
  -930
  -1,001
  -1,052
  -1,080
  -1,084
  -1,064
  -1,022
  -961
  -884
  -795
  -700
  -603
  -507
  -417
  -335
  -263
  -201
  -150
Current shareholders' claim on cash, %
  50.0
  12.2
  3.0
  0.7
  0.2
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

FINANCIAL RATIOS  of  Blueprint Medicines (BPMC)

Valuation Ratios
P/E Ratio -23.7
Price to Sales 61.8
Price to Book 8.1
Price to Tangible Book
Price to Cash Flow -69.2
Price to Free Cash Flow -64.1
Growth Rates
Sales Growth Rate 154.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -60%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 71
Current Ratio 0
LT Debt to Equity 0.5%
Total Debt to Equity 1.9%
Interest Coverage 0
Management Effectiveness
Return On Assets -31.6%
Ret/ On Assets - 3 Yr. Avg. -75.3%
Return On Total Capital -39.7%
Ret/ On T. Cap. - 3 Yr. Avg. -90.6%
Return On Equity -40.9%
Return On Equity - 3 Yr. Avg. -114.2%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -253.6%
EBITDA Margin - 3 Yr. Avg. -242.1%
Operating Margin -257.1%
Oper. Margin - 3 Yr. Avg. -243.3%
Pre-Tax Margin -260.7%
Pre-Tax Margin - 3 Yr. Avg. -247.5%
Net Profit Margin -260.7%
Net Profit Margin - 3 Yr. Avg. -247.5%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

BPMC stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the BPMC stock intrinsic value calculation we used $21.426 million for the last fiscal year's total revenue generated by Blueprint Medicines. The default revenue input number comes from 0001 income statement of Blueprint Medicines. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our BPMC stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for BPMC is calculated based on our internal credit rating of Blueprint Medicines, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Blueprint Medicines.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of BPMC stock the variable cost ratio is equal to 361.9%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for BPMC stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 7.9% for Blueprint Medicines.

Corporate tax rate of 27% is the nominal tax rate for Blueprint Medicines. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the BPMC stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for BPMC are equal to 72.7%.

Life of production assets of 9.7 years is the average useful life of capital assets used in Blueprint Medicines operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for BPMC is equal to -160.8%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $623.97 million for Blueprint Medicines - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 43.837 million for Blueprint Medicines is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Blueprint Medicines at the current share price and the inputted number of shares is $2.3 billion.

RELATED COMPANIES Price Int.Val. Rating
ALXN Alexion Pharma 119.68 55.95  str.sell
CELG Celgene 69.98 340.31  str.buy
JNJ Johnson&Johnso 144.50 176.79  buy
XOMA XOMA 13.53 0.17  str.sell
AZN AstraZeneca AD 41.40 162.71  str.buy

COMPANY NEWS

▶ Blueprint Medicines: 3Q Earnings Snapshot   [07:44AM  Associated Press]
▶ What Blueprint Medicines Just Said About Its Future   [Aug-02-18 06:31AM  Motley Fool]
▶ Blueprint Medicines: 2Q Earnings Snapshot   [07:34AM  Associated Press]
▶ Conquering cancer in the Windy City   [Jun-01-18 04:40PM  CNBC Videos]
▶ The Big Thing to Watch at ASCO 2018   [May-31-18 06:01PM  Motley Fool]
▶ Blueprint Medicines Shows Market Leadership With Jump To 93 RS Rating   [May-25-18 03:00AM  Investor's Business Daily]
▶ Blueprint CEO traces biotech's rapid growth at opening of new HQ   [May-24-18 12:41PM  American City Business Journals]
▶ Blueprint Medicines: 1Q Earnings Snapshot   [May-02-18 08:24AM  Associated Press]
▶ How Blueprint Medicines Got The Blues   [Apr-24-18 08:27AM  Forbes]
▶ Blueprint Medicines reports 4Q loss   [07:31AM  Associated Press]
▶ Company News For Dec 12, 2017   [10:47AM  Zacks]
▶ Biotech Stocks Soar On Trial Data At Hematology Conference   [Dec-11-17 04:31PM  Investor's Business Daily]
▶ Cambridge biotechs among big winners at ASH blood disease conference   [Dec-10-17 09:25PM  American City Business Journals]
▶ Blueprint Medicines reports 3Q loss   [07:28AM  Associated Press]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.